SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune Inc is trending following positive topline Phase 2b data for its MASH drug, pemvidutide, which demonstrated statistically significant improvements in key non-invasive liver tests and a favorable tolerability profile, with the FDA supporting a registrational Phase 3 trial. The community is actively discussing whether the initial market reaction is a "sell the news" event or a strategic accumulation by institutions, amid ongoing speculation about potential partnerships or a buyout to fund the next stage of development for this promising asset.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics is trending as the community eagerly awaits FDA guidance on its lead drug, Belapectin, for MASH cirrhosis, fueling widespread speculation around potential conditional approval, partnership, or buyout. Recent analyst upgrades and ongoing discussions about significant short interest are also driving conversation, with many anticipating a notable market event for this promising biotech.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike (NKE) is a major talking point after its recent earnings report, which, despite an EPS and revenue beat, presented cautious guidance with anticipated shrinking sales and margins, notably in Greater China, alongside margin pressure from tariffs. This has sparked a divided community, with many seeing the sharp stock dip as an overreaction and a prime long-term buying opportunity, while others remain concerned about market share losses to competitors and the perceived weak leadership during the earnings call.

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Amicus Therapeutics Inc

Amicus Therapeutics (FOLD) is trending due to the announcement of its acquisition by BioMarin Pharmaceutical for $14.50 per share in cash. The community views this as a strategic move to bolster BioMarin's leadership in rare diseases by integrating Amicus's key commercial products like Galafold. Investors are actively discussing the implications of this acquisition and speculating on potential future buyouts within the biotech sector.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing a surge in conversation following multiple analyst upgrades, with price targets raised to $25, coupled with the significant expansion of its "Universal Hands-Free" assisted driving feature across millions of miles of roads. The community is actively discussing Rivian's transition from a pure EV manufacturer to a leader in autonomy and software, driven by its in-house AI chip development and upcoming R2 launch, igniting hopes for a major short squeeze.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to the highly anticipated launch of its new 'Predictions' app, signaling a strategic expansion into event-based betting. The community is actively discussing its potential market impact and how recent regulatory crackdowns on competitor prediction platforms might benefit DraftKings' federally regulated approach.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber (WYFI) is trending due to a significant 10-year, $865 million colocation agreement with Nscale for AI infrastructure at its NC-1 data center, marking a major catalyst for the company. The community is buzzing with excitement over this long-term AI revenue visibility and the stock's notably low free float. This deal firmly positions WhiteFiber within the booming AI data center sector, drawing increased attention to its growth potential.

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Biomarin Pharmaceutical Inc. - Registered Shares

BioMarin Pharmaceutical is actively trending due to its recent multi-billion dollar acquisition of Amicus Therapeutics, which significantly expands its rare disease portfolio with key treatments like Galafold and Pombiliti. The community is discussing how this strategic move makes BioMarin's ambitious revenue targets more tangible, aiming to accelerate growth and strengthen its financial outlook.

Starfighters Space Inc

Starfighters Space Inc ($FJET) is a trending topic following its public trading debut, with investors captivated by its unique position as a commercial supersonic aircraft operator from NASA's Kennedy Space Center. The community is enthusiastically comparing it to established aerospace leaders and high-growth tech giants, driven by its perceived potential in the burgeoning space industry. This excitement is contributing to its high volatility and active discussion among traders.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending after delivering an impressive earnings beat and raising its fiscal year outlook, fueled by stronger domestic package volumes and ongoing cost-cutting initiatives. While many in the community are bullish on its operational execution and market position, there is active discussion around the stock's price volatility and options market dynamics following the report, alongside concerns about broader macroeconomic headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Ormat Technologies (ORA) Up 1.8% Since Last Earnings Report?

Ormat Technologies (ORA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Top Research Reports for Tesla, BlackRock & Welltower

Tesla sets delivery records but braces for weaker Q4 as tax credits expire and competition heats up.

Cheniere Partners Q3 Earnings Miss Estimates on Higher Expenses

CQP Q3 earnings fall short of estimates as higher operating costs weigh on results despite revenue gains.

Cheniere Energy Partners, L.P. (CQP) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Cheniere Energy Partners, L.P. (CQP) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Cheniere Reports Third Quarter 2025 Results, Reconfirms Full Year 2025 EBITDA Guidance and Raises Full Year 2025 Distributable Cash Flow Guidance

Cheniere Energy, Inc. (Cheniere) (NYSE: LNG) today announced its financial results for the third quarter 2025. THIRD QUARTER 2025 SUMMARY FINANCIAL RESULTS (in billions) Three Months Ended September...

Cheniere Partners Reports Third Quarter 2025 Results and Reconfirms Full Year 2025 Distribution Guidance

Cheniere Energy Partners, L.P. (Cheniere Partners) (NYSE: CQP) today announced its financial results for third quarter 2025. HIGHLIGHTS During the three and nine months ended September 30, 2025...

Cheniere Partners Q2 Earnings Miss Estimates, Revenues Beat

CQP's Q2 profit misses estimates as LNG volumes fall, but revenues rise to $2.5B, topping forecasts.

Top Analyst Reports for Alphabet, Bank of America & Roche

Delek Logistics Set to Report Q1 Earnings: What's in the Cards?

Cheniere Energy: Stifel lowers PT, downgrades to 'Sell' on limited upside

Investing.com-- Stifel analysts downgraded their rating for  Cheniere Energy Partners  LP (NYSE:CQP) (CQP) and reduced the price target citing limited upside and overvaluation after a recent rally.

Cheniere Energy Partners LP engages in the operations of liquefied natural gas. It provides LNG to integrated energy companies, utilities, and energy trading companies around the world. The company was founded in 2006 and is headquartered in Houston, TX.

Cheniere Energy Partners LP - Unit

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$1.10	--	--	N/A
Q3 '25	$1.02	$0.80	-21.33%	MISSED
Q2 '25	$0.94	$0.91	-3.44%	MISSED
Q1 '25	$1.11	$1.08	-2.65%	MISSED
Q4 '24	$1.07	$1.05	-2.32%	MISSED

CQP
Cheniere Energy Partners LP.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CQP News

CQPCheniere Energy Partners LP.